Related Experiment Video
Updated: May 30, 2025
11:07
Focal Laser Ablation of Prostate Cancer: An Office Procedure
Published on: March 30, 2021
7.7K
MR-Guided Transrectal Focal Laser Ablation for Localized Low- and Intermediate-Risk Prostate Cancer: Initial Outcomes
Yvonne Wimper1, Lauren P W Te Molder1, J P Michiel Sedelaar2
1Department of Medical Imaging, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Journal of Vascular and Interventional Radiology : JVIR
|January 30, 2025
Summary
Magnetic resonance imaging-guided focal laser ablation (FLA) is a feasible and safe treatment for localized prostate cancer (PCa). This study shows promising short-term oncologic and functional outcomes for patients with low-to-intermediate-risk PCa.
Area of Science:
- Oncology
- Medical Imaging
- Minimally Invasive Surgery
Background:
- Prostate cancer (PCa) is a common malignancy requiring effective localized treatment options.
- Magnetic resonance (MR) imaging offers precise visualization for image-guided interventions.
- Focal laser ablation (FLA) is an emerging minimally invasive technique for tissue ablation.
Purpose of the Study:
- To assess the feasibility and safety of MR imaging-guided FLA for localized prostate cancer (ISUP Grade 1-3).
- To evaluate the short-term oncologic and functional outcomes of this integrated system.
Main Methods:
- Prospective study of 10 males (mean age 66) with low-to-intermediate-risk PCa.
- Treatment with MR imaging-guided FLA using an integrated system with MR thermometry.
- Primary endpoints: technical success, adverse events (AEs), and 12-month local tumor progression-free survival.
Main Results:
- 100% technical success rate in all patients.
- Three AEs observed: 2 urinary tract infections (SIR Grade 2) and 1 acute urinary retention (SIR Grade 3).
- 80% local tumor progression-free survival at 12 months; median tumor coverage 100%.
Conclusions:
- MR imaging-guided FLA is a feasible and safe procedure for low-to-intermediate-risk prostate cancer.
- The integrated system demonstrated promising short-term oncologic control and functional preservation.
